# Senti Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Senti Biosciences, Inc.). ## Overview Senti Biosciences, Inc. is a U.S.-based biotechnology company focused on developing gene circuit-based cell and gene therapies. Its platform is used to engineer programmable therapeutic cells and related product candidates for oncology and other serious diseases, with research and development centered in the United States. ## Products & services • Gene circuit platform for programmable cell therapies • SENTI-202 oncology product candidate • SENTI-301A gene circuit program • Preclinical and clinical development services • Third-party collaboration and manufacturing arrangements - **Gene circuit platform** (70%) — Core synthetic biology platform used to design programmable therapeutic cells. - **Lead product candidates** (20%) — Therapeutic programs such as SENTI-202 and SENTI-301A in development. - **Research and development services** (10%) — Internal discovery, preclinical, clinical, and regulatory development work. - Gene circuit platform for programmable cell therapies - SENTI-202 oncology product candidate - SENTI-301A gene circuit program - Preclinical and clinical development services - Third-party collaboration and manufacturing arrangements ## Customers Senti Biosciences does not currently sell commercial products; its primary counterparties are clinical investigators, research collaborators, contract manufacturers, and potential licensing or commercialization partners. In the future, its end customers would be hospitals, physicians, and patients receiving approved cell or gene therapies, typically in oncology and other severe diseases. - **Clinical trial investigators and sites** (primary) — They administer studies of SENTI-202 and other candidates and generate clinical data. - **Biopharma collaboration partners** (primary) — They may license, co-develop, or help commercialize platform-derived programs. - **Contract manufacturers and suppliers** (primary) — They provide reagents, materials, and manufacturing capacity for development. - **Future healthcare providers** (emerging) — Hospitals and treatment centers would buy approved therapies if commercialization succeeds. - Clinical trial sites and investigators running studies of product candidates - Research collaborators using or evaluating the gene circuit platform - Contract manufacturers and suppliers supporting development batches - Potential pharma/biotech partners for co-development or commercialization - Future hospitals and treatment centers if products reach approval ## Geography Senti Biosciences is headquartered and operates primarily in the United States, where its long-lived assets are located and where most research and development activity is conducted. The company also has collaboration exposure in China through the SN301A program with Celest Therapeutics, which introduces cross-border operational and regulatory complexity. - United States is the core operating base and asset location - R&D and management functions are centered in the U.S. - China exposure comes through a partnered investigator-sponsored trial - International collaboration adds regulatory and execution complexity - No current revenue concentration disclosure was provided ## Strategy Senti Biosciences is focused on advancing its gene circuit platform and moving lead programs through preclinical and clinical development. It also relies on external collaborators and manufacturers to extend its technical capabilities while preserving capital for research, regulatory, and trial execution. - **Advance lead clinical programs** (short-term) — Clinical data are needed to validate the platform and support future approvals or partnerships. - **Prioritize pipeline and capital allocation** (short-term) — Early-stage biotech companies must focus resources on the most promising programs. - **Rely on external manufacturing and collaborators** (medium-term) — The company lacks internal commercial infrastructure and depends on third parties for execution. - Advance SENTI-202 through clinical development - Prioritize pipeline programs based on data and feasibility - Use collaborators for manufacturing and trial execution - Build evidence for the gene circuit platform in oncology - Seek future commercialization or partnering options ## Risks The company faces the typical risks of an early-stage biotech developer: clinical failure, regulatory setbacks, and dependence on third parties for manufacturing and trials. Its platform and product candidates also face supply-chain, scale-up, and product liability risks, while cross-border collaborations add operational and geopolitical exposure. - **Clinical development failure or delay** [high] — Early-stage product candidates may not show sufficient safety or efficacy. - **Manufacturing scale-up risk** [high] — Cell and gene therapies require reproducible, high-quality manufacturing at scale. - **Third-party dependency risk** [high] — The company relies on external parties for trials, preclinical work, and manufacturing. - **Supply chain and reagent variability** [medium] — Limited vendors and inconsistent inputs can disrupt development and affect outcomes. - **International collaboration and regulatory risk** [medium] — Cross-border work can be affected by local regulation, politics, and operational issues. - Clinical trials may fail or be delayed, reducing development value - Manufacturing scale-up may be difficult or inconsistent - Dependence on third-party manufacturers and CROs creates execution risk - Supply shortages or reagent variability can affect product quality - International collaborations add regulatory and political risk ## Accounting For a development-stage biotech, the most important accounting judgments are R&D expense classification, fair value measurements, and lease/sublease accounting. Senti also has related-party items tied to GeneFab, including derivative fair value estimates and sublease income recognition, which can materially affect reported results even without product revenue. - **Research and development expense classification** — Drives the largest operating expense line in a development-stage biotech - **Fair value measurement of related-party derivatives** — Can create non-cash gains or losses in the income statement - **Sublease income recognition and reversals** — Can materially change other income and reported period comparability - **Lease accounting** — Influences operating expense presentation and cash flow timing - R&D expense timing depends on clinical, preclinical, and manufacturing spend - Fair value estimates affect GeneFab option and economic share liabilities - Sublease accounting can create non-cash income or reversals - Lease accounting affects headquarters and related-party occupancy costs - No product revenue means operating results are driven by expense recognition --- *Last updated: 2026-04-29T04:58:05.011294+00:00*